Q4 2026
Ends Dec 31, 2026
Revenue
$56.7B
$56.6B to $56.7B
EPS
0.00
0.00 to 0.00
No analyst count
EPS: No analyst count
Apr 28, 01:59 AM UTC
stable/analyst-estimates
Consumer Defensive
Live Price
Offline$34.05
+0.00% today
Window Change
+0.00%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) is a Consumer Defensive stock with a market cap of $431.69B and listed on OTC. The stock last traded around $34.05 and up 0.0% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +0.2%, EPS growth of -64.1%, a dividend yield of 1.8%. What stands out right now is revenue +0.2%, EPS -64.1%, free cash flow +180.3% with operating margin 9.0% and ROIC 6.8%. The dividend is present but secondary, with a yield around 1.8%. Valuation already assumes a fairly strong business story at P/E 118.1 and price/sales 2.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KBYPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KBYPF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KBYPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for KBYPF and SPY.
EPS Consensus
0.00
Range 0.00 -> 0.00
No analyst count
Revenue Outlook
$56.7B
Range $56.6B -> $56.7B
No analyst count
vs prior: +27.3%Price Target
--
-- -> --
No analyst count
Recommendations
--
No recommendation feed
No date
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Next Earnings
EPS --
Revenue --
No analyst count
EPS Revisions
No recent EPS revision rows
0 revision rows
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.